Opinions
David Burrows
Alexion Pharmaceuticals
ALXN-Q
COMMENT
May 23, 2017
$104.640
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Top Short There's a small problem with this stock. Around March 20 they are going to be releasing some news that might have major influence on the stock. Had a very long base around $34 and thinks this is where the stock is heading. Volumes are not large. Use a $1 trailing stop.
biotechnology
pharmaceutical
Advertising
Biotech can be a big win or a big loss. A lot of companies have binary outcomes, their product either works or it doesn’t. This company recently had a significant disappointment. US investors are not very sympathetic to these types of situations. They shoot first and ask questions later. If you want to own biotech, he would suggest you own a tech with lots of different products, or buy an ETF that gives you a basket. This one is a broken stock.